4th Quarter - Report
BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 12, 2024 | $120,000 | Replaced |
| 4th Quarter - Amendment | Jul 17, 2026 | $140,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
ORPHAN Cures Act H.R. 5539; S. 3131 Promising Pathways Act HR 4408; S. 1906 PAHPA H.R.469 PAHPA S.R. 2333 Innovation in Pediatric Drugs Act of 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMANDA MALAKOFF | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.